HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.

AbstractINTRODUCTION:
Rivaroxaban does not require monitoring nor frequent dose adjustment. However, searching for the optimal dose in the individual patient may be useful in some situations.
AIM:
To determine which coagulation assay could be used to assess the impact of rivaroxaban on haemostasis and provide guidelines for the interpretation of routine lab tests.
MATERIALS:
Rivaroxaban was spiked at concentrations ranging from 11 to 1,090 ng/mL in plateletpoor plasma. A large panel of coagulation assays was tested.
RESULTS:
A concentration dependent prolongation of aPTT, PT, dPT, PiCT was observed. PT and dPT were the most sensitive chronometric assays but results varied depending on the reagent (Triniclot PT Excel S>Recombiplastin 2G>Neoplastin R>Neoplastin CI+>Triniclot PT Excel>Triniclot PT HTF>Innovin). FXa chromogenic assays showed the highest sensitivity. In TGA, Cmax was the most sensitive parameter with the tissue factor induced pathway. Rivaroxaban interferes on haemostasis diagnostic tests such the measurement of clotting factors, fibrinogen, antithrombin, proteins C and S, activated protein-C resistance and Xa-based chomogenic assays.
CONCLUSIONS:
PT may be used as screening test to assess the risk of bleedings. A more specific and sensitive assay such as Biophen DiXaI using calibrators should be used to confirm the concentration of rivaroxaban. We also propose cut-off associated with a bleeding or thrombosis risk based on pharmacokinetic studies. Standardization of the time between the last intake of rivaroxaban and the sampling is mandatory.
AuthorsJonathan Douxfils, François Mullier, Claire Loosen, Christian Chatelain, Bernard Chatelain, Jean-Michel Dogné
JournalThrombosis research (Thromb Res) Vol. 130 Issue 6 Pg. 956-66 (Dec 2012) ISSN: 1879-2472 [Electronic] United States
PMID23006523 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2012 Elsevier Ltd. All rights reserved.
Chemical References
  • Anticoagulants
  • Morpholines
  • Thiophenes
  • Rivaroxaban
Topics
  • Anticoagulants (administration & dosage)
  • Blood Coagulation (drug effects)
  • Blood Coagulation Tests (methods)
  • Humans
  • Morpholines (administration & dosage)
  • Prothrombin Time
  • Rivaroxaban
  • Thiophenes (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: